Page 1 | Search Results | Hematology, ASH Education Program

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Evidence-Based Minireview: What is the optimal timing of anti–PD-1 antibodies in relapsed classical Hodgkin lymphoma?

Pamela Blair Allen, Ann S. LaCasce

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 249–251.

https://doi.org/10.1182/hematology.2019000077

Published: 2019

Journal Articles

Management of older Hodgkin lymphoma patients

Andrew M. Evens, Jordan Carter, Kah Poh Loh, Kevin A. David

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 233–242.

https://doi.org/10.1182/hematology.2019000028

Published: 2019

Journal Articles

Where does PD-1 blockade fit in HL therapy?

Alex F. Herrera

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 213–220.

https://doi.org/10.1182/asheducation-2018.1.213

Published: 2018

Journal Articles

Risk-adapted therapy for advanced-stage Hodgkin lymphoma

Michael A. Spinner, Ranjana H. Advani

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 200–206.

https://doi.org/10.1182/asheducation-2018.1.200

Published: 2018

Journal Articles

Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution

Nancy L. Bartlett

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 317–323.

https://doi.org/10.1182/asheducation-2017.1.317

Published: 2017

Journal Articles

Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly

Marco Ruella, Pierre Soubeyran

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 432–436.

https://doi.org/10.1182/asheducation-2016.1.432

Published: 2016

Journal Articles

Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet?

Peter W. M. Johnson

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 316–322.

https://doi.org/10.1182/asheducation-2016.1.316

Published: 2016

Journal Articles

Double-hit lymphomas: current paradigms and novel treatment approaches

Kieron Dunleavy

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 107–112.

https://doi.org/10.1182/asheducation-2014.1.107

Published: 2014

Journal Articles

Transplantation for mantle cell lymphoma: is it the right thing to do?

Michael E. Williams

Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 568–574.

https://doi.org/10.1182/asheducation-2013.1.568

Published: 2013

Journal Articles

Treatment strategies for aggressive lymphomas: what works?

Wyndham H. Wilson

Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 584–590.

https://doi.org/10.1182/asheducation-2013.1.584

Published: 2013

Journal Articles

Interim PET-CT in the management of diffuse large B-cell lymphoma

Craig H. Moskowitz

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 397–401.

https://doi.org/10.1182/asheducation.V2012.1.397.3798512

Published: 2012

Journal Articles

Optimal Therapy of Advanced Hodgkin Lymphoma

Ranjana Advani

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 310–316.

https://doi.org/10.1182/asheducation-2011.1.310

Published: 2011

Journal Articles

The Past: What We Have Learned in the Last Decade

Peter Borchmann, Andreas Engert

Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 101–107.

https://doi.org/10.1182/asheducation-2010.1.101

Published: 2010

Journal Articles

Standard therapy of advanced Hodgkin lymphoma

John Kuruvilla

Hematology Am Soc Hematol Educ Program (2009) 2009 (1): 497–506.

https://doi.org/10.1182/asheducation-2009.1.497

Published: 2009

Journal Articles

Induction Therapy in Multiple Myeloma

Jean-Luc Harousseau

Hematology Am Soc Hematol Educ Program (2008) 2008 (1): 306–312.

https://doi.org/10.1182/asheducation-2008.1.306

Published: 2008

Journal Articles

Antibody Therapy in Aggressive Lymphomas

Thomas M. Habermann

Hematology Am Soc Hematol Educ Program (2007) 2007 (1): 257–264.

https://doi.org/10.1182/asheducation-2007.1.257

Published: 2007

Journal Articles

Evolving Approaches to Primary Treatment of Hodgkin Lymphoma

Joseph M. Connors

Hematology Am Soc Hematol Educ Program (2005) 2005 (1): 239–244.

https://doi.org/10.1182/asheducation-2005.1.239

Published: 2005

NARROW

Evidence-Based Minireview: What is the optimal timing of anti–PD-1 antibodies in relapsed classical Hodgkin lymphoma?

Management of older Hodgkin lymphoma patients

Where does PD-1 blockade fit in HL therapy?

Risk-adapted therapy for advanced-stage Hodgkin lymphoma

Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution

Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly

Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet?

Double-hit lymphomas: current paradigms and novel treatment approaches

Transplantation for mantle cell lymphoma: is it the right thing to do?

Treatment strategies for aggressive lymphomas: what works?

Interim PET-CT in the management of diffuse large B-cell lymphoma

Optimal Therapy of Advanced Hodgkin Lymphoma

The Past: What We Have Learned in the Last Decade

Standard therapy of advanced Hodgkin lymphoma

Induction Therapy in Multiple Myeloma

Antibody Therapy in Aggressive Lymphomas

Evolving Approaches to Primary Treatment of Hodgkin Lymphoma

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only